Author pages are created from data sourced from our academic publisher partnerships and public sources.
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
- Byung-Hee Oh, J. Mitchell, James R. Herron, J. Chung, Mahmudul Khan, D. Keefe
- Journal of the American College of Cardiology
- 20 March 2007
OBJECTIVES This dose-ranging study evaluated the antihypertensive efficacy and tolerability of aliskiren in patients with mild-to-moderate hypertension. BACKGROUND Low blood pressure (BP) control… Expand
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
Background—Loss of negative feedback inhibition of renin release during chronic treatment with an angiotensin-converting enzyme (ACE) inhibitor leads to a compensatory rise in renin secretion and… Expand
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial
Objectives This double-blind study compared long-term efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren and the angiotensin-converting enzyme inhibitor ramipril alone and… Expand
- D. Keefe
- 1 October 2002
Trastuzumab is a monoclonal antibody used for the treatment of metastatic breast carcinoma in women whose tumors overexpress the HER2 protein. Cardiotoxicity has been reported to occur with… Expand
Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension
Current guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommend first-line treatment with a thiazide diuretic but do not… Expand
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis.
- M. Weir, C. Bush, D. Anderson, J. Zhang, D. Keefe, A. Satlin
- Journal of the American Society of Hypertension…
- 1 July 2007
The antihypertensive efficacy and safety of the direct renin inhibitor aliskiren were assessed in a pooled analysis of data from seven randomized, multicenter studies. Data were available for 7,045… Expand
Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension
- T. Kushiro, H. Itakura, Y. Abo, H. Gotou, S. Terao, D. Keefe
- Hypertension Research
- 1 December 2006
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients… Expand
Aliskiren for Geriatric Lowering of Systolic Hypertension: a randomized controlled trial
- D. Duprez, M. Munger, J. Botha, D. Keefe, A. Charney
- Journal of Human Hypertension
- 1 September 2010
Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind,… Expand
Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients
J Clin Hypertens (Greenwich). 2011;13:506–516. ©2011 Wiley Periodicals, Inc.